RESUMEN
BACKGROUND: Propolis exhibits therapeutic properties due to the presence of phenolic acids, esters, and flavonoids. The scope of this study was to develop a nano-vesicular formulation and establish a three-dimensional (3D) spheroid model in which lung cancer is recapitulated. RESULTS: Niosome vesicles doped with galangin-rich propolis extract were synthesized by the ether injection method using a cholesterol : surfactant mass ratio of 1 : 3 at 40 °C for 1 h. Formulated niosomes were administered to 3D lung cancer spheroid model and the cytotoxicity was compared with that of a two-dimensional (2D) setting. The galangin content was determined as 86 µg mg-1 propolis extract by ultra-performance liquid chromatography (UPLC). The particle size of loaded niosome was 151 ± 2.84 nm with a polydispersity index (PDI) of about 0.232, and an encapsulation efficiency of 70% was achieved. CONCLUSION: The decrease in cell viability and the scattering in the 3D spheroids of A549 lung cancer cells treated with propolis-loaded niosomes were notable, indicating a profound cytotoxic effect and suggesting that they can be utilized as an effective nano-vesicle. © 2020 Society of Chemical Industry.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Própolis/química , Própolis/farmacología , Células A549 , Supervivencia Celular/efectos de los fármacos , Composición de Medicamentos , Humanos , Liposomas/química , Liposomas/farmacología , Neoplasias Pulmonares/fisiopatología , Nanopartículas/química , Tamaño de la Partícula , Esferoides Celulares/citología , Esferoides Celulares/efectos de los fármacosRESUMEN
We aimed to develop a molecularly imprinted polymeric systems with using penicillin G as a template molecule for removal of the antibiotic residues from environmental samples. Firstly, Pen-G-imprinted poly (2-hydroxyethyl methacrylate-N-methacryloyl-L-alanine) [p(HEMA-MAAL)] nanopolymers were synthesized by surfactant-free emulsion polymerization method. Then, template molecule (Pen-G) was extracted from nanopolymers. Synthesized nanopolymers were characterized by different methods such as Fourier-transform infrared spectroscopy (FTIR), elemental and zeta-size analysis, scanning electron microscope (SEM), and surface area calculations. Nanopolymers have 60.38 nm average size and 1034.22 m2/g specific surface area. System parameters on Pen-G adsorption onto Pen-G imprint nanopolymers were investigated at different conditions. The specific adsorption value (Qmax) of molecularly impirinted p(HEMA-MAAL) nanopolymers was found 71.91 g/g for Pen-G in 5 mg/mL Pen-G initial concentration. Pen-G adsorption of molecularly imprinted nanopolymers was 15 times more than non-imprinted polymer. It is shown that obtained p(HEMA-MAAL) nanopolymer was a reuseable product which protected its adsorption capacity of 98.9% after 5th adsorption-desorption cycle. In conclusion, we suggest a method to develop a nanostructure, selective, low-cost molecularly imprinted polymeric systems with using penicillin G as a template molecule for removal of the antibiotic residues.
Asunto(s)
Monitoreo del Ambiente , Modelos Químicos , Impresión Molecular , Nanoestructuras , Penicilina G/química , Adsorción , PolímerosRESUMEN
Serum proteins can generally be considered a good source for the illness' indication and are precious resources to detect diseases such as inflammation, cancer, diabetes, malnutrition, cardiovascular diseases, Alzheimer's, other autoimmune diseases, and infections. However, one of the biggest difficulties for proteomic studies is that the majority of serum protein mass consists of only a few proteins. Albumin and Immunoglobulin (IgG) constitute 80% of total serum protein. In this study, dye ligand affinity-based hydrogel membranes were proposed as new materials with micron mesh structures. Micron mesh p(HEMA) hydrogel membranes were synthesized by using the UV-photopolymerization method, then modified with Reactive Red 241 (RR241) dye ligand to increase the affinity towards IgG. Characterizations of synthesized micron mesh p(HEMA)-RR241 hydrogel membranes were also performed. It was demonstrated by the characterization studies that; the dye was successfully incorporated into the membrane structure with the amount of 119.38 mg/g. The hydrophilic property of the hydrogel membrane was demonstrated by swelling tests and the swelling value of dye modified membrane was found to be 8 times higher than that of the plain membrane. Micron network structure, as well as the porosity, were demonstrated with SEM/ESEM studies. Optimization of IgG adsorption conditions was also studied at different parameters (pH, temperature, ion strength, initial IgG concentration). Optimum pH, temperature, and ionic strength were found to be 6.5, 25 °C, 0.05 M, respectively, and the maximum IgG absorption value was 10.27 mg/g. Finally, it was shown that the proposed materials can be used repeatedly by 5 adsorption-desorption cycles.
Asunto(s)
Hidrogeles , Membranas Artificiales , Adsorción , Concentración de Iones de Hidrógeno , Inmunoglobulina G/química , Ligandos , Metacrilatos , ProteómicaRESUMEN
Coronavirus disease 2019 (COVID-19) is a major public health concern currently. To date, there are no approved antiviral drugs or vaccines against this transmissible disease. This report sheds light on available information for a better understanding of clinical trials and pharmacotherapy related to COVID-19. MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, WHO, and EU clinical trial sites were used to perform comparative analysis. Information was collected on the use of therapeutic agents for human therapy in patients with COVID-19 up to May 2020. We have extracted data from 60 clinical trials. Amongst these trials, 34 were from the European Union database of clinical trials and 26 from the National Institute of Health. The data selection procedure includes active, completed, and recruitment in progress status. Most of the clinical trials are ongoing and hence, there is a lack of precise results for the treatment.There is a lack of high-quality clinical evidence. The protocol to be developed requires large randomized clinical trials with a combination of available drugs and prospective therapies. We propose the usage of a large number of cases and different statistical analyses to conduct systematic clinical trials. This could provide comprehensive information about the clinical trial and potential therapeutic progress.